(A) Schematic illustration showing the application of AQ4N-hCe6-liposome for activation of AQ4N prodrug. Reproduced with permission from Feng et al.43 Copyright 2016, American Chemical Society.
(B) Schematic illustration showing the application of YS-DMONs for synergistic cancer therapy. (i) Intracellular delivery of GOD and AQ4N caused by GSH-triggered cleavage of tetrasulfide bond; (ii) GOD-mediated catalytic reaction led to oxygen consumption and formation of hypoxic environment; (iii) hypoxia-induced activation of AQ4N prodrug. Reproduced with permission from Yang et al.44 Copyright 2018, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
(C) Schematic illustration showing the application of AC-TGH for activation of TPZ prodrug. Reproduced with permission from Zhang et al.45 Copyright 2018, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.